Story one
The biotech founder and the lockup
- Company
- Clinical-stage biotech, recently public
- Situation
- Most of her net worth in one stock
- Timeline
- Two years
- Worked with
- A partner, an associate, company counsel
The situation
A scientist-founder whose company had gone public eighteen months earlier. Her 180-day lockup had long since ended, but she hadn’t sold a share. Every time the stock dropped she didn’t want to sell low, and every time it rose she didn’t want to miss more upside. Meanwhile, a single trial readout could halve her net worth.
What we did
We started with a number: how much she needed, invested plainly, to never have to work again. Then we worked backward to how much stock that meant selling. With company counsel, we set up a 10b5-1 trading plan that sold on a fixed schedule over eighteen months, so the decision was made once, in advance, instead of every morning.
“I didn’t need a prediction. I needed to stop checking the price at 5 a.m.”
Where it landed
The plan ran as written. She kept a meaningful stake in the company she believes in, and the rest now pays for the life she’d already planned. She still checks the stock, just not first thing.